Skip to main content

Table 2 Univariate analysis of OS (A) in the whole MBC population (n = 244) and (B) in the BM population (n = 86): main results

From: The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases

 

Whole MBC population (n = 244)

BM population (n = 86)

Parameter

Median OS in months (95 CI%)

P-value

Median OS in months (95 CI%)

P-value

Initial characteristics

 Tumor biology group

  HER2+ HR+

  HER2+ HR-

  HER2- HR+

  Triple negative

28.6 (16.5 – NC)

31.6 (20.2–34.5)

12.4 (10.4–22.5)

6.3 (4.5–10.4)

< 0.001

14.4 (8.1–20.1)

8.7 (2.6–20.2)

9.7 (2.6–16.2)

4.6 (2.0–8.5)

0.0598

 PR status

  Negative

  Positive

12.5 (10.6–17.8)

21.7 (16.2–35.6)

0.044

8.1 (4.6–10.4)

16.2 (9.7–21.7)

0.119

 HER2 status

  Negative

  Positive

10.4 (8.4–12.4)

28.7 (20.1–33.9)

< 0.001

6.4 (4.2–10.0)

12.1 (8.1–19.1)

0.037

 Histological grade (SBR)

  1 or 2

  3

20.9 (15.1–31.6)

11.1 (9.5–15.0)

0.012

10.4 (6.4–20.6)

8.1 (4.2–10.4)

0.117

 Metastatic status at BC diagnosis

  M0

  M1

13.6 (10.5–16.5)

27.2 (13.7–32.1)

0.016

8.5 (4.7–10.0)

11.6 (4.2–20.9)

0.056

 Adjuvant or néoadjuvant CT

  No

  Yes

20.7 (16.8–31.6)

12.5 (10.3–15.5)

0.009

11.6 (8.4–20.3)

6.8 (3.3–10.3)

0.007

Characteristics at the time of the serum sample

 ECOG status

  Score 0

  Score 1

  Score 2

  Score 3

34.5 (20.9–63.6)

16.5 (12.1–22.5)

6.8 (3.8–16.8)

2.0 (1.4–2.6)

< 0.001

14.4 (10.0 – NC)

12.1 (8.4–19.1)

8.5 (1.5–17.6)

2.0 (1.2–4.6)

< 0.001

 Number of lines of CT

  0 line

  1 or 2 line(s)

  >  2 lines

17.8 (15.0–27.8)

20.9 (16.3–32.0)

6.4 (4.6–10.4)

< 0.001

8.5 (4.7–17.6)

12.4 (8.4–20.3)

4.6 (2.2–9.7)

0.007

 Number of metastatic sites

  1–3

  ≥4

30.7 (19.1–59.2)

11.7 (9.9–15.0)

< 0.001

10.3 (5.6–19.1)

9.7 (4.7–12.1)

0.309

 Location of metastatic sites

  Bone and/or subcutaneous only

  Visceral

63.6 (16.5 – NC)

14.4 (11.4–19.1)

0.0016

NC

9.7 (5.6–10.8)

0.843

 Brain metastases

  Absent

  Present

30.4 (16.8–34.5)

9.7 (5.6–10.8)

< 0.001

-

-

 Liver metastases

  Absent

  Present

28.7 (14.9–36.8)

12.4 (10.6–17.2)

< 0.001

6.8 (3.8–10.4)

9.8 (4.9–13.6)

0.377

 Subcutaneous metastases

  Absent

  Present

19.2 (13.7–22.6)

10.4 (4.6–15.2)

0.0034

10.0 (8.1–13.6)

4.7 (1.4–9.8)

0.011

 Metastases of other sites

  Absent

  Present

20.9 (16.2–30.7)

10.6 (6.4–12.5)

< 0.001

10.0 (8.1–15.5)

5.3 (2.8–11.6)

0.876

 Serum albumin level

  Normal

  Low

14.4 (11.1–19.4)

1.6 (1.1–2.4)

< 0.001

10.0 (6.8–12.4)

1.4 (0.7–2.6)

< 0.001

 Serum CEA

  Normal

  Elevated

20.1 (15.5–28.6)

11.1 (8.7–13.6)

0.003

10.0 (4.7–15.5)

9.7 (3.3–12.1)

0.483

 Serum CA 15–3

  Normal

  Elevated

28.7 (19.4–59.2)

11.4 (9.7–14.4)

< 0.001

10.4 (6.8–20.1)

8.5 (4.0–10.4)

0.096

 Serum HER2 ECD (cut-off 15 ng/mL)

  Normal

  Elevated

21.7 (15.2–31.6

11.4 (8.9–14.4)

< 0.001

10.3 (4.7–21.7)

8.7 (4.6–12.1)

0.085

 Serum Tau (cut-off 0.74 pg/mL*)

  Normal

  Elevated

33.2 (19.2–42.8)

12.4 (10.6–16.3)

0.007

12.1 (6.8–28.6)

8.5 (4.6–10.4)

0.060

 Serum Tau (cut-off 1.24 pg/mL**)

  Normal

  Elevated

23.0 (15.0–33.2)

11.3 (9.5–16.3)

0.0011

10.3 (4.6–12.4)

8.7 (4.9–12.4)

0.942

 Serum Tau (cut-off 3.17 pg/mL***)

  Normal

  Elevated

20.6 (16.2–30.4)

9.5 (4.9–10.8)

< 0.001

10.3 (5.3–13.6)

8.7 (2.6–10.8)

0.389

  1. Abbreviations: PR: progesterone-receptors; SBR: Scarf, Bloom and Richardson; BC: breast cancer; CT: chemotherapy; CEA: Carcinoembryonic Antigen; CA 15–3: Cancer Antigen 15–3; HER2-ECD: HER2-extra-cellular domain; NC: not calculated; NSE: Neuron Specific Enolase; MMP-9: Matrix Metalloproteinase 9
  2. *cut-off corresponding to the first quartile
  3. **cut-off corresponding to the median
  4. ***cut-off corresponding to the third quartile